LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The summit brings together leaders in health, culture, science, and community to advance health equity for Black men and families, inspired by the music, legacy, and lived experiences of De La Soul. The event is rooted in De La Soul's song "Good Health," written following the passing of founding member David Jolicoeur (Trugoy the Dove).
Developed in collaboration with Blacksmith holdings, the program reflects De La Soul's evolution from musical pioneers to wellness advocates and will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness. LIXTE stated that the summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA, while creating a space to connect scientific innovation with communities most impacted by health disparities.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company has demonstrated that its lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology called activation lethality, advancing a new treatment paradigm covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company's latest news and updates are available in its newsroom at https://ibn.fm/LIXT.
The sponsorship of this health equity summit represents a strategic alignment between corporate scientific advancement and community health initiatives. By participating in events that address systemic health disparities, pharmaceutical companies like LIXTE can bridge the gap between laboratory research and real-world health outcomes. The focus on Black men and families is particularly significant given documented health disparities in cancer outcomes, cardiovascular disease, and mental health services within these communities.
Events like the Good Health Summit create platforms for dialogue between medical researchers, healthcare providers, community leaders, and affected populations. This type of engagement can inform research priorities, improve clinical trial diversity, and enhance trust in medical institutions. For LIXTE specifically, the sponsorship supports its broader mission while potentially creating opportunities for community-based research partnerships and increasing awareness of its innovative cancer therapies among populations that have been historically underserved by medical advancements.
